ClinicalTrials.gg
Enrolling by invitationNCT06763965Updated Mar 23, 2026

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

A Phase 1/2 interventional study of BioTTT001 injection in Recurrent High-grade Glioma, sponsored by Beijing Bio-Targeting Therapeutics Technology Co., Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Beijing Bio-Targeting Therapeutics Technology Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 162 studies in Glioma with a site in China — 70 open to participants now, 82 under way, 3 of them phase 3. Glioma · China.

Planned enrollment
69th of 112
30 · median 40
Started
2024
with 16 others
Phase 1/2
19 of 162
6 open now
Primary completion
2027-07
later than 53 of 81 live
Registered
126th of 162
by date

Among the 162 studies in Glioma with a site in China, this one is the 69th largest by planned enrollment of the 112 interventional ones that give a count, is one of 17 that started in 2024, is one of 19 in phase 1/2, reaches primary completion later than 53 of the 81 other live ones, and was the 126th registered.

Glioma

1,454 studies on the registry are indexed under Glioma; 350 are open to participants now.

Browse Glioma studies →

Open to participants now

70 of the 162 studies in Glioma with a site in China are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Glioma with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.

Read the detailed description

Phase Ⅰb Dose Escalation Study:Three dose groups were established in the dose escalation phase, namely 1.0×10\^10 VP, 5.0×10\^10 VP and 2.5×10\^11 VP. The traditional "3+3" dose escalation method was used for dose escalation, with at least 3 subjects enrolled in each dose group, and each subject received only one corresponding dose until the MTD and/or RP2D were determined.It is planned to enroll 12\~18 subjects, and the final sample size of enrollment depends on the number of DLT, the number of dose groups that are escalated before the DLT is observed, and the determination of the MTD.

Phase Ⅱ Dose Expansion Study:In this phase, one dose group was selected for a dose expansion study to further evaluate the efficacy and safety of BioTTT001 in patients with recurrent/progressive high-grade glioma.It is planned to select 1 dosage that may be used for phase Ⅰ clinical research to expand enrollment, and it is planned to enroll 10\~30 subjects.

03

Conditions studied

  • Recurrent High-grade Glioma

Keywords

  • Oncolytic virus
  • IL-12
  • Adenovirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older, both male and female are eligible;
  2. Patients with high-grade glioma who have recurred/progressed after receiving standard therapy as confirmed by histopathological confirmation meeting the 2021 World Health Organization (WHO) classification criteria for central nervous system tumors;
  3. Performance Score (KPS) ≥ 60 points (see Appendix 2);
  4. Suitable for placement of Ommaya sac as judged by the investigator to be eligible for administration;
  5. Estimated survival ≥ 3 months;
  6. Good organ function;
  7. Voluntary participation and ability to sign form prior to the start of study-related procedures, after explaining the content of the study;
  8. Subjects of and sexually active partners must be willing to use a medically approved and effective method of , such as a double-barrier method of contraception, during treatment and for 6 months after the last dose, and the male agrees not to donate sperm;
  9. Females of childbearing potential, must have a negative blood pregnancy test result within 7 days prior to the first dose and be willing to undergo additional pregnancy tests during the study. Females of childbearing potential who have not undergone surgical sterilization (i.e., bilateral tubal ligation, bilateral oophorectomy, or total hysterectomy) or are not ; Menopause is the absence of menopause for 12 months in women over ≥ age of 45 and the exclusion of other causes of amenorrhea. In addition, serum follicle-stimulating hormone (FSH) levels in women under 50 years of age must be in the postmenopausal range for menopause to be confirmed;
  10. Good compliance, willing and able to follow all research procedures, and cooperate with observation and follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Received anti-tumor drug therapy such as radiotherapy, chemotherapy, biological therapy, endocrine therapy, targeted therapy and other anti-tumor drugs within 4 weeks before the first dose (excluding immunotherapy, nitrosourea, mitomycin C, oral fluorouracil, small molecule targeted drugs, and traditional Chinese medicines with anti-tumor indications);
  2. Treatment with any other unmarketed drug within 4 weeks prior to the first dose;
  3. Surgical surgery of major organs within 4 weeks prior to the first dose (excluding live puncture) or have had significant trauma, or need to undergo elective surgery during the study;
  4. Those who have a history of cell therapy, gene therapy, and oncolytic virus therapy in the past;
  5. Those who have known or suspected to the active ingredients of the study drug, , and imaging contrast agents;
  6. Those who have a history of organ transplantation or plan to undergo organ transplantation during the study;
  7. Patients with active infection or uncontrollable infection requiring intravenous systemic therapy, or fever of unknown cause > 38.5°C during the screening period and before the first dose;
  8. Accompanied by severe coagulation disorder or other evidence of obvious bleeding risk; history of gastrointestinal bleeding; Any other ≥ grade 2 bleeding event within the past 6 months;
  9. Subjects who have received systemic (>10 mg/day of prednisone or equivalent) or other within 14 days prior to the first dose; except in the following cases: use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroid treatments; short-term use of corticosteroids for prophylactic treatment (e.g., prevention of contrast agent allergy);
  10. Adverse reactions from previous anti-tumor treatments have not yet recovered to ≤ Grade 1 according to CTCAE 5.0 (except for toxicities deemed to pose no safety risk by the investigator, such as hair loss, Grade 2 peripheral neuropathy, etc.);
  11. History of immunodeficiency, including positive antibody test;
  12. Active (HBsAg positive and HBV-DNA > 500 IU/ml or lower limit of detection at the study center [only if the study center's detection limit is higher than 500 IU/ml]); active (HCV antibody positive and HCV-RNA > the detection limit at the study center), positive treponema pallidum antibody for syphilis;
  13. Hypertension poorly controlled as judged by the investigator (arterial hypertension not controlled despite standard treatment: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);
  14. History of severe cardiovascular disease, such as: ventricular arrhythmia requiring clinical intervention; >480 ms; acute coronary syndrome, congestive heart failure, stroke, or other grade III or higher cardiovascular events within 6 months prior to first administration; (NYHA) functional class ≥II (see Appendix 4) or (LVEF) \<50%;
  15. Presence of other untreated within the past 3 years or currently, except for carcinoma in situ that is considered clinically curable, such as in situ cervical cancer and basal cell carcinoma;
  16. Active or past diseases with potential for recurrence (including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except clinically stable autoimmune thyroiditis;
  17. Received live attenuated or recombinant vaccines within 4 weeks before first administration, or received inactivated vaccines within 2 weeks before first administration;
  18. Previous immunotherapy with immune-related adverse events (irAE) of grade ≥3;
  19. Tumorous lesions in the brainstem, cerebellum, posterior cranial fossa, or spinal cord, or presence of ;
  20. Diffuse subependymal and subarachnoid space disease;
  21. Patients whose lesions are closely related to the ventricles, posing a risk of intraventricular dissemination (patients judged by the investigator that the oncolytic virus cannot directly reach the ventricles after administration may be included);
  22. History of encephalitis, multiple sclerosis, or other central nervous system infections;
  23. Patients with brain herniation syndrome;
  24. Known alcohol or drug dependence;
  25. Patients with psychiatric disorders or poor compliance;
  26. Pregnant or breastfeeding women;
  27. Participants who, in the opinion of the investigator, have other serious systemic diseases or other reasons that make them unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    BioTTT001 injection

    BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.

    Biological: BioTTT001 injection

Interventions

  • BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    The incidence and severity of all types of adverse events evaluated based on NCI-CTCAE5.0

    Time frame: 28 days within BioTTT001 injection

  2. DLT、MTD and/or RP2D

    Maximum tolerated dose (MTD)、Dose-limiting toxicity(DLT)、Recommended Phase II Dose(RP2D)

    Time frame: 28 days within BioTTT001 injection

  3. OS12

    12-month survival rate

    Time frame: 12 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 32 months after the start.

Of 70 phase 1/2 interventional studies under Glioma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 104. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 8, 2025
StartActual
Nov 26, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06763965
Lead sponsor
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Nov 26, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Mar 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant Oncolytic Adenovirus 5 Encoding Non-secreting Interleukin-12 BioTTT001

Start the discussion